JP2016532667A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532667A5
JP2016532667A5 JP2016521758A JP2016521758A JP2016532667A5 JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5 JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical combination
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059387 external-priority patent/WO2015054175A1/en
Publication of JP2016532667A publication Critical patent/JP2016532667A/ja
Publication of JP2016532667A5 publication Critical patent/JP2016532667A5/ja
Priority to JP2018225287A priority Critical patent/JP7403950B2/ja
Pending legal-status Critical Current

Links

JP2016521758A 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ Pending JP2016532667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018225287A JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361889640P 2013-10-11 2013-10-11
US61/889,640 2013-10-11
US201361911089P 2013-12-03 2013-12-03
US61/911,089 2013-12-03
PCT/US2014/059387 WO2015054175A1 (en) 2013-10-11 2014-10-07 Combinations of histone deactylase inhibitors and immunomodulatory drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018225287A Division JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Publications (2)

Publication Number Publication Date
JP2016532667A JP2016532667A (ja) 2016-10-20
JP2016532667A5 true JP2016532667A5 (enExample) 2017-11-16

Family

ID=52810182

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016521758A Pending JP2016532667A (ja) 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Country Status (17)

Country Link
US (2) US20150105358A1 (enExample)
EP (1) EP3054939A4 (enExample)
JP (4) JP2016532667A (enExample)
KR (1) KR20160060143A (enExample)
CN (1) CN105722507A (enExample)
AU (1) AU2014332147A1 (enExample)
CA (1) CA2926808A1 (enExample)
CL (1) CL2016000838A1 (enExample)
CR (1) CR20160200A (enExample)
EA (1) EA201690753A1 (enExample)
IL (1) IL244923A0 (enExample)
MX (1) MX2016004604A (enExample)
NI (1) NI201600051A (enExample)
PE (1) PE20161342A1 (enExample)
PH (1) PH12016500649A1 (enExample)
SG (1) SG11201602791RA (enExample)
WO (1) WO2015054175A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2526093T (pt) 2010-01-22 2016-11-25 Acetylon Pharmaceuticals Inc Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos
EA025345B1 (ru) 2010-11-16 2016-12-30 Эситайлон Фармасьютикалз, Инк. Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и фармацевтические композиции для лечения заболевания, обусловленного hdac6, включающие эти соединения
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
ES2929576T3 (es) * 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
US9278963B2 (en) * 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
EP3054939A4 (en) * 2013-10-11 2017-12-13 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
ES2918673T3 (es) 2013-10-24 2022-07-19 Mayo Found Medical Education & Res Tratamiento de enfermedades poliquísticas con un inhibidor de HDAC6
JP6535670B2 (ja) 2013-12-03 2019-06-26 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US9833466B2 (en) 2014-07-07 2017-12-05 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
CN107438436A (zh) 2014-12-05 2017-12-05 摩德纳和雷焦艾米利亚大学 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合
CA2970500C (en) 2014-12-12 2023-08-29 Acetylon Pharmaceuticals, Inc. Piperidine derivatives as hdac1/2 inhibitors
EP3303304B1 (en) 2015-06-08 2019-11-20 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
WO2017143237A1 (en) * 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
EP3468559B1 (en) * 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
WO2018031472A1 (en) 2016-08-08 2018-02-15 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
JP7090611B2 (ja) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド1(pd-l1)阻害剤とを含む医薬組み合わせ物及びその使用方法
WO2018098348A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
MX2023012095A (es) 2021-04-23 2023-12-14 Tenaya Therapeutics Inc Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
TW202308619A (zh) 2021-05-04 2023-03-01 美商特納亞治療股份有限公司 用於治療代謝疾病和hfpef的hdac6抑制劑
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
PT2526093T (pt) * 2010-01-22 2016-11-25 Acetylon Pharmaceuticals Inc Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos
EA025345B1 (ru) * 2010-11-16 2016-12-30 Эситайлон Фармасьютикалз, Инк. Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и фармацевтические композиции для лечения заболевания, обусловленного hdac6, включающие эти соединения
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
EP3054939A4 (en) * 2013-10-11 2017-12-13 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs

Similar Documents

Publication Publication Date Title
JP2016532667A5 (enExample)
JP2017524735A5 (enExample)
JP2016536286A5 (enExample)
JP2016515561A5 (enExample)
JP2017518334A5 (enExample)
JP2014507446A5 (enExample)
MY170656A (en) Kinase inhibitors
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
JP2015078230A5 (enExample)
EA201790088A1 (ru) Ингибиторы syk
JP2014508804A5 (enExample)
JP2016518337A5 (enExample)
JP2016514159A5 (enExample)
JP2013509429A5 (enExample)
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
WO2015187542A8 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
JP2011088926A5 (enExample)
PH12014501278A1 (en) Kinase inhibitors
MX376029B (es) Compuestos de isoindol.
JP2016515550A5 (enExample)